CAT
Caterpillar Inc.
CAT has the edge over DCH overall, supported by stronger modeled upside and lower modeled downside.
DCH
Dauch Corporation
DCH offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
CAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
CAT's revenue, profitability, cash flow and balance sheet are all currently healthy.
DCH Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Weak |
DCH's revenue is currently strong, but its profitability, cash flow and balance sheet are under pressure.
CAT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $380 | -37% |
| Fair | 18x | $461 | -24% |
| Forward | 20x | $605 | — |
| Current | 24x | $605 | — |
| Expensive | 33x | $840 | +39% |
Historical ranges are pointers, not guarantees.
CAT's PE is in its expensive range at 24x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its fair range.
DCH PE Valuation
DCH has no meaningful PE right now: it lost money over the past year.
CAT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Low |
Analysts expect earnings and revenue growth for CAT, with profitability improving. However, they disagree widely on these estimates.
DCH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for DCH, with profitability improving. However, they disagree widely on these estimates.
CAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $29.73 | +17% |
| Q3 2026 | $25.48 | +31% |
| Q2 2026 | $23.23 | +18% |
| Q1 2026 | $20.08 | -2% |
| Q4 2025 | $18.81 | -15% |
| Q3 2025 | $19.46 | -9.7% |
| Q2 2025 | $19.64 | -10% |
| Q1 2025 | $20.50 | -7.4% |
| Q4 2024 | $22.05 | +9.6% |
CAT has the edge over DCH on earnings quality, reporting a profit while its opponent remains loss making.
DCH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.86 | — |
| Q3 2026 | -$1.33 | -491% |
| Q2 2026 | -$1.07 | -406% |
| Q1 2026 | -$0.75 | -517% |
| Q4 2025 | -$0.17 | -159% |
| Q3 2025 | $0.34 | +48% |
| Q2 2025 | $0.35 | +$0.35 |
| Q1 2025 | $0.18 | +$0.26 |
| Q4 2024 | $0.29 | +$0.58 |
DCH has swung to a loss: it lost $1.33 per share over the past year, after a profit the year before.
CAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7B | +17% |
| Q2 2026 | $20.5B | +24% |
| Q1 2026 | $17.4B | +22% |
| Q4 2025 | $19.1B | +18% |
| Q3 2025 | $17.6B | +9.5% |
| Q2 2025 | $16.6B | -0.7% |
| Q1 2025 | $14.2B | -9.8% |
| Q4 2024 | $16.2B | -5% |
CAT has the edge over DCH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +3.1 points |
| Q2 2026 | 21% | +3.6 points |
| Q1 2026 | 18% | -0.4 points |
| Q4 2025 | 14% | -4.1 points |
| Q3 2025 | 17% | -2.2 points |
| Q2 2025 | 17% | -3.6 points |
| Q1 2025 | 18% | -4.2 points |
| Q4 2024 | 18% | -0.3 points |
CAT has the edge over DCH on profitability, with a higher operating margin.
DCH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.9B | +93% |
| Q2 2026 | $3B | +92% |
| Q1 2026 | $2.4B | +69% |
| Q4 2025 | $1.4B | +0.2% |
| Q3 2025 | $1.5B | 0% |
| Q2 2025 | $1.5B | -5.9% |
| Q1 2025 | $1.4B | -12% |
| Q4 2024 | $1.4B | -5.6% |
DCH's revenue has grown year over year for five quarters in a row: $2.9B last quarter, up 93% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.5% | -0.8 points |
| Q2 2026 | 3.4% | -0.2 points |
| Q1 2026 | -1.4% | -4.4 points |
| Q4 2025 | -2.4% | -5.1 points |
| Q3 2025 | 3.2% | +0.5 points |
| Q2 2025 | 3.6% | -1.7 points |
| Q1 2025 | 3% | -1.8 points |
| Q4 2024 | 2.6% | +0.7 points |
DCH's operating margin was 2.5% last quarter, down 0.8 points from the same quarter a year ago.
CAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +19% |
| Q2 2026 | $3.8B | +47% |
| Q1 2026 | $1.1B | +97% |
| Q4 2025 | $2.7B | +0.1% |
| Q3 2025 | $3.1B | -1.5% |
| Q2 2025 | $2.6B | -4.2% |
| Q1 2025 | $579M | -63% |
| Q4 2024 | $2.7B | -22% |
CAT has the edge over DCH on cash generation, producing positive trailing cash flow while its opponent burns cash.
DCH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $54.7M | -31% |
| Q2 2026 | $9.2M | -73% |
| Q1 2026 | -$168M | -$154.6M |
| Q4 2025 | $54.7M | -25% |
| Q3 2025 | $79.2M | +13% |
| Q2 2025 | $34.6M | -63% |
| Q1 2025 | -$13.4M | +$16.8M |
| Q4 2024 | $73.2M | +$76.3M |
DCH's free cash flow has turned negative after years in the green: −$49M over the past year.
CAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -1.6M shares |
| 1 year | -2.1% | -9.9M shares |
| 3 years | -10% | -51.7M shares |
| 5 years | -16% | -86.7M shares |
| Available history | -19% | -107M shares |
CAT has the edge over DCH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.2B |
| Q2 2026 | $1.5B |
| Q1 2026 | $5B |
| Q4 2025 | $340M |
| Q3 2025 | $362M |
| Q2 2025 | $828M |
| Q1 2025 | $3.7B |
| Q4 2024 | $640M |
CAT spent $8.1B buying back its own shares over the past year, up 47% from the year before.
DCH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +100K shares |
| 1 year | +100% | +119M shares |
| 3 years | +103% | +120M shares |
| 5 years | +108% | +123M shares |
| Available history | +112% | +125M shares |
DCH has 238M diluted shares, up 100% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $700,000 |
| Q2 2026 | $2M |
| Q1 2026 | $6.2M |
| Q4 2025 | $100,000 |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $2.7M |
| Q4 2024 | — |
DCH spent $9M buying back its own shares over the past year, about three times what it spent the year before.
CAT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | 2.0x | Healthy |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | 1.6x | Healthy |
CAT has the edge over DCH on leverage, with a lower net debt burden relative to earnings.
DCH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.0x | High |
| Q2 2026 | 6.0x | High |
| Q1 2026 | 7.5x | High |
| Q4 2025 | 5.9x | High |
| Q3 2025 | 3.0x | Elevated |
| Q2 2025 | 3.3x | Elevated |
| Q1 2025 | 3.1x | Elevated |
| Q4 2024 | 3.0x | Moderate |
DCH's net debt is about 5.0 years of its operating earnings (EBITDA), up from 3.0 years a year ago.
CAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.7 | Neutral |
| Stochastic | 6.7 | Oversold |
CAT's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
DCH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.5 | Neutral |
| Stochastic | 7.8 | Oversold |
DCH's weekly RSI is 39 (neutral) and its Stochastic is 8 (oversold).
CAT PE vs Industrials Sector
| Metric | CAT | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 24x | 1.1% below |
| PE % | 69 | 58 | 11 pts above |
CAT is trading at 24x earnings, in line with the Industrials sector's median of 24x.
DCH PE vs Industrials Sector
| Metric | DCH | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 24x | — |
DCH has no meaningful PE right now: it lost money over the past year.
CAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $709.0 | 15% below |
| 20 week MA | $797.0 | 24% below |
| 50 week MA | $771.3 | 22% below |
| 100 week MA | $586.7 | 3.2% above |
| 200 week MA | $443.1 | 37% above |
CAT has the edge over DCH on trend strength, trading above more of its moving averages.
DCH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.02 | 7.4% below |
| 20 week MA | $5.63 | 17% below |
| 50 week MA | $6.16 | 25% below |
| 100 week MA | $5.63 | 17% below |
| 200 week MA | $6.52 | 29% below |
DCH is in a downtrend: it's below all five of its weekly moving averages, and 29% below its 200-week average.
CAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $148.3 | $179.6 | +21% |
| 2021 | $179.6 | $206.2 | +15% |
| 2022 | $206.2 | $239.9 | +16% |
| 2023 | $239.9 | $295.7 | +23% |
| 2024 | $295.7 | $364.9 | +23% |
| 2025 | $364.9 | $583.0 | +60% |
| 2026 YTD | $583.0 | $605.3 | +3.8% |
CAT has the edge over DCH on returns for 2026, with the stronger performance.
DCH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.6 | $8.23 | -23% |
| 2021 | $8.23 | $9.34 | +13% |
| 2022 | $9.34 | $7.65 | -18% |
| 2023 | $7.65 | $8.81 | +15% |
| 2024 | $8.81 | $5.86 | -33% |
| 2025 | $5.86 | $6.46 | +10% |
| 2026 YTD | $6.46 | $4.65 | -28% |
DCH has finished lower in three of the last six years. It's down 28% so far in 2026.